Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
RNA modification systems as therapeutic targets.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
RNA modification systems as therapeutic targets.
RNA modification systems as therapeutic targets. Nat Rev Drug Discov. 2026 01; 25(1):59-78.
View in:
PubMed
subject areas
Adenosine
Animals
Humans
Methyltransferases
Molecular Targeted Therapy
Neoplasms
RNA
RNA Processing, Post-Transcriptional
authors with profiles
Chuan He